PMID- 35580444
OWN - NLM
STAT- MEDLINE
DCOM- 20220608
LR  - 20220621
IS  - 1878-3279 (Electronic)
IS  - 0171-2985 (Linking)
VI  - 227
IP  - 3
DP  - 2022 May
TI  - The development of a candidate of desensitization vaccines against Der f 2 nearly 
      without IgE-binding activity.
PG  - 152217
LID - S0171-2985(22)00043-2 [pii]
LID - 10.1016/j.imbio.2022.152217 [doi]
AB  - Considering the important role of Der f 2 in house dust mites mediating allergic 
      diseases and allergic adverse effects during allergen-specific immunotherapy 
      (AIT), we intend to develop a candidate of desensitization vaccines against Der f 
      2 without allergenicity. According to the reported immunoglobulin E (IgE)-binding 
      B and T cell epitopes of Der f 2, four candidates of desensitization vaccines 
      against Der f 2 were developed. Recombinant wild-type Der f 2 (rWt-Der f 2) 
      preserved conformational and linear IgE-binding B epitopes. rWt-Der f 2 
      linearized by reduction and alkylation reactions (rWt-Der f 2 (red/alk)) and 
      recombinant modified-type Der f 2 (rMt-Der f 2) were developed via destroying 
      conformational and linear IgE-binding B epitopes respectively. rMt-Der f 2 
      linearized by reduction and alkylation reactions (rMt-Der f 2 (red/alk)) was 
      developed by destroying conformational and linear IgE-binding B epitopes. T cell 
      epitopes of 4 candidates were preserved. The change of their IgE-binding activity 
      was determined by enzyme linked immunosorbent assay (ELISA), western blot and 
      inhibition ELISA. Compared with rWt-Der f 2, the IgE-binding activity of rWt-Der 
      f 2 (red/alk), rMt-Der f 2 and rMt-Der f 2 (red/alk) all decreased, which was 
      consistent with the result of western blot. The IgE-binding activity of rMt-Der f 
      2 and rMt-Der f 2 (red/alk) was not significantly different (P = 0.0863 > 0.05), 
      which was comparable to that of their corresponding negative controls (P = 0.3488 
      and 0.4459, both > 0.05). The result of inhibition ELISA also showed that their 
      IgE-binding activity decreased, and rMt-Der f 2 (red/alk) was the lowest. 
      Conclusively, we developed the candidate of desensitization vaccines against Der 
      f 2, rMt-Der f 2 or rMt-Der f 2 (red/alk), nearly without allergenicity, which 
      would potentially prevent HDM allergic patients from allergic adverse effects 
      caused by AIT.
CI  - Copyright (c) 2022. Published by Elsevier GmbH.
FAU - Ling, Xiao-Jing
AU  - Ling XJ
AD  - Precision Medicine Center, The First Affiliated Hospital of Gannan Medical 
      University, Ganzhou, China; Department of Clinical Pharmacy, School of Pharmacy, 
      Nanjing Medical University, Nanjing, China; Clinical Allergy Center, The First 
      Affiliated Hospital of Nanjing Medical University, Nanjing, China.
FAU - Pan, Chen
AU  - Pan C
AD  - School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 
      Nanjing, China.
FAU - Tan, Ling-Xiao
AU  - Tan LX
AD  - Department of Respiratory Medicine, Children's Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Zhu, Ying
AU  - Zhu Y
AD  - Department of Blood Transfusion, The First Affiliated Hospital of Gannan Medical 
      University, Ganzhou, China.
FAU - Yang, Yu-Xing
AU  - Yang YX
AD  - Precision Medicine Center, The First Affiliated Hospital of Gannan Medical 
      University, Ganzhou, China.
FAU - Zeng, Xiao-Fei
AU  - Zeng XF
AD  - Precision Medicine Center, The First Affiliated Hospital of Gannan Medical 
      University, Ganzhou, China.
FAU - Sun, Jin-Lyu
AU  - Sun JL
AD  - Department of Allergy, State Key Laboratory of Complex Severe and Rare Diseases, 
      Peking Union Medical College Hospital, Chinese Academy of Medical Science and 
      Peking Union Medical College, Beijing, China. Electronic address: 
      sunjinlv@pumch.cn.
FAU - Wei, Ji-Fu
AU  - Wei JF
AD  - Department of Pharmacy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer 
      Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 
      China; Department of Clinical Pharmacy, School of Pharmacy, Nanjing Medical 
      University, Nanjing, China; Clinical Allergy Center, The First Affiliated 
      Hospital of Nanjing Medical University, Nanjing, China. Electronic address: 
      weijifu@njmu.edu.cn.
FAU - Lu, Chen
AU  - Lu C
AD  - Precision Medicine Center, The First Affiliated Hospital of Gannan Medical 
      University, Ganzhou, China. Electronic address: gzfylc@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220412
PL  - Netherlands
TA  - Immunobiology
JT  - Immunobiology
JID - 8002742
RN  - 0 (Allergens)
RN  - 0 (Antigens, Dermatophagoides)
RN  - 0 (Arthropod Proteins)
RN  - 0 (Dermatophagoides farinae antigen f 2)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (Vaccines)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Allergens
MH  - Antigens, Dermatophagoides
MH  - Arthropod Proteins
MH  - Epitopes, T-Lymphocyte
MH  - Humans
MH  - *Hypersensitivity/prevention & control
MH  - Immunoglobulin E
MH  - Receptor Protein-Tyrosine Kinases
MH  - *Vaccines
OTO - NOTNLM
OT  - Conformational IgE-binding B epitopes
OT  - Der f 2
OT  - Desensitization vaccines
OT  - Linear IgE-binding B epitopes
EDAT- 2022/05/18 06:00
MHDA- 2022/06/09 06:00
CRDT- 2022/05/17 18:19
PHST- 2022/02/01 00:00 [received]
PHST- 2022/04/09 00:00 [revised]
PHST- 2022/04/09 00:00 [accepted]
PHST- 2022/05/18 06:00 [pubmed]
PHST- 2022/06/09 06:00 [medline]
PHST- 2022/05/17 18:19 [entrez]
AID - S0171-2985(22)00043-2 [pii]
AID - 10.1016/j.imbio.2022.152217 [doi]
PST - ppublish
SO  - Immunobiology. 2022 May;227(3):152217. doi: 10.1016/j.imbio.2022.152217. Epub 
      2022 Apr 12.